FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:58-59 January 6, 2000 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Durham, S. R.

To the Editor: The study by Durham et al. (Aug. 12 issue)¹ of the clinical efficacy of grass-pollen immunotherapy has a complex design. According to the authors, the study is a randomized, double-blind, placebo-controlled study of the discontinuation of immunotherapy in patients with rhinitis. The authors conclude that "immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission."

The design of the study has a flaw that we believe invalidates their conclusion: it did not include a randomized group that received placebo to control for the spontaneous course of rhinitis. In 1988, patients were randomly assigned to . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.